Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) said it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025 after the market close. The company noted it does not intend to host a conference call.

Spero is a clinical-stage biopharmaceutical company focused on novel treatments for rare diseases and multi-drug resistant bacterial infections.

News Market Reaction – SPRO

+3.40%

1 alert

+3.40% News Effect

On the day this news was published, SPRO gained 3.40%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com

Spero Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@sperotherapeutics.com

Spero Media Inquiries: 
media@sperotherapeutics.com

FAQ

When will Spero Therapeutics (SPRO) report its Q3 2025 results?

Spero will report Q3 2025 financial results on Thursday, November 13, 2025, after market close.

Will Spero Therapeutics (SPRO) host a conference call for the Q3 2025 results?

No; the company said it does not intend to host a conference call for the Q3 2025 results.

How will Spero Therapeutics (SPRO) provide the November 13, 2025 business update?

The company will provide a business update when it reports results on November 13, 2025 after market close.

What is Spero Therapeutics (SPRO) known for as of November 4, 2025?

Spero is a clinical-stage biopharmaceutical company focused on treatments for rare diseases and multi-drug resistant bacterial infections.

Will investors be able to ask questions during Spero's Q3 2025 report on November 13, 2025?

The company indicated it does not intend to host a conference call, so no live Q&A is planned.